Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the price is fair and strategically sound, results aren't expected until 2029, making it a long-term growth play for the biotech company.